Research programme: stroke therapy - BioTime/University of California Los Angeles

Drug Profile

Research programme: stroke therapy - BioTime/University of California Los Angeles

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioTime; University of California at Los Angeles
  • Class Growth factors; Nerve growth factors
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Stroke

Most Recent Events

  • 22 Jan 2018 Stroke therapy is still in preclinical studies in the US
  • 17 Jan 2018 BioTime has patent protection for its Stroke Therapy in USA
  • 17 Jan 2018 BioTime has patent protection for Pluripotent cell technology in USA, Japan, Singapore, India and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top